BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 14617000)

  • 1. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
    Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
    Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.
    Biedermann B; Gil D; Bowen DT; Crocker PR
    Leuk Res; 2007 Feb; 31(2):211-20. PubMed ID: 16828866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
    Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
    Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
    Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced myeloid specificity of CD117 compared with CD13 and CD33.
    Nomdedéu JF; Mateu R; Altès A; Llorente A; Rio C; Estivill C; López O; Ubeda J; Rubiol E
    Leuk Res; 1999 Apr; 23(4):341-7. PubMed ID: 10229319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
    Alsabeh R; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells.
    Takeshita A; Shinjo K; Ohnishi K; Ohno R
    Br J Haematol; 1996 Apr; 93(1):18-21. PubMed ID: 8611458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface marker expression in acute myeloid leukaemia at first relapse.
    Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D
    Br J Haematol; 1992 May; 81(1):40-4. PubMed ID: 1381608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
    Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
    Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
    Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.
    Cornish AL; Freeman S; Forbes G; Ni J; Zhang M; Cepeda M; Gentz R; Augustus M; Carter KC; Crocker PR
    Blood; 1998 Sep; 92(6):2123-32. PubMed ID: 9731071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic and functional characterization of CD33(+)CD34(+) cells in human cord blood of preterm neonates.
    Jin CH; Takada H; Nomura A; Takahata Y; Nakayama H; Kajiwara M; Nakano H; Hara T
    Exp Hematol; 2000 Oct; 28(10):1174-80. PubMed ID: 11027836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
    Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
    Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase.
    Martín-Henao GA; Quiroga R; Sureda A; García J
    Am J Hematol; 1999 Jul; 61(3):178-86. PubMed ID: 10398310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in CD33 intensity between various myeloid neoplasms.
    Jilani I; Estey E; Huh Y; Joe Y; Manshouri T; Yared M; Giles F; Kantarjian H; Cortes J; Thomas D; Keating M; Freireich E; Albitar M
    Am J Clin Pathol; 2002 Oct; 118(4):560-6. PubMed ID: 12375643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia.
    Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S
    Blood; 1992 Apr; 79(7):1811-6. PubMed ID: 1373089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
    Nguyen DH; Ball ED; Varki A
    Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multidrug resistance in acute leukemia].
    Takeshita A; Ohno R
    Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.